Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.

[1]  N. Harbeck,et al.  Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04 , 2023, Cancer Research.

[2]  M. Paulli,et al.  Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature , 2023, Breast Cancer Research and Treatment.

[3]  Wencheng Zhang,et al.  Receptor discordance among primary tumors, brain metastases and extra-brain metastases in patients with breast cancer. , 2023, Future oncology.

[4]  D. Rimm,et al.  Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[5]  P. Kranke,et al.  Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases , 2022, Journal of Cancer Research and Clinical Oncology.

[6]  Yizi Jin,et al.  Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases , 2022, International journal of cancer.

[7]  G. Viale,et al.  Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status , 2022, Virchows Archiv.

[8]  Yi-Feng Ren,et al.  Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions , 2022, Cancers.

[9]  S. Tyekucheva,et al.  Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. , 2022, JAMA oncology.

[10]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[11]  M. Fassan,et al.  HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment , 2022, npj Breast Cancer.

[12]  Yan Song,et al.  Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer , 2022, Laboratory Investigation.

[13]  F. André,et al.  Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) , 2022, Cancer Research.

[14]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[15]  C. Criscitiello,et al.  Evolution of low HER2 expression between early and advanced-stage breast cancer. , 2022, European journal of cancer.

[16]  M. Fassan,et al.  Evolution of HER2-low expression from primary to recurrent breast cancer , 2021, NPJ breast cancer.

[17]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[18]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Khoury.  Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules , 2018, American journal of clinical pathology.

[21]  Helene Dérand,et al.  A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2 , 2017, Modern Pathology.

[22]  Y. Kamata,et al.  Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. , 2015, Oncology reports.

[23]  Rohit Bhargava,et al.  The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma , 2012, Modern Pathology.

[24]  J. Cuzick,et al.  ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer , 2009, Breast Cancer Research.

[25]  M. Untch,et al.  Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Baselga,et al.  Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity , 2009, Oncogene.

[27]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2008, Nature.

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[29]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.